Abstract
This meta-analysis assesses the recent Food and Drug Administration (FDA)-approved antifungal, rezafungin, for treating candidemia and invasive candidiasis— both are significant health concerns with limited treatment options. Two randomized controlled trials comparing rezafungin to caspofungin were meta-analyzed, revealing no significant differences in global cure rates and 30-day all-cause mortality. While rezafungin's unique attributes, like a novel mechanism and once-weekly dosing, may enhance patient adherence, concerns arise about its clinical relevance given the substantial investment. The study emphasizes the need for ongoing research, post-marketing surveillance, and real-world data to determine rezafungin's true value in managing these life-threatening fungal infections. Despite FDA approval, further investigation is warranted for a comprehensive understanding of rezafungin's efficacy and safety.
Keywords: Rezafungin; Candidemia; Invasive candidiasis; Meta-analysis; Antifungal therapy
Recommended Citation
Sarfraz, Zouina; Nasir, Zeeshan; Javad, Faheem; Khan, Aden; Shah, Bushra; Khalid, Musfira; Sarfraz, Azza; Sarfraz, Muzna; Minhas, Amna; and Gondal, Suchal Atta
(2024)
"Game Changer or More of the Same? A Comparative Meta-Analysis of Rezafungin and Caspofungin in Treating Candidemia and Invasive Candidiasis,"
Journal of Community Hospital Internal Medicine Perspectives: Vol. 14:
Iss.
5, Article 1.
DOI: 10.55729/2000-9666.1391
Available at:
https://scholarlycommons.gbmc.org/jchimp/vol14/iss5/1
